Known targets — ChEMBL curated mechanism
ADRA2AADRA2BADRA2CADRB2AGTR1AVPR1AAVPR1BAVPR2BDKRB2CALCRCHRNA3CHRNB4ESR1ESR2GHSRGNRHRGSC1HSPA8MALT1MC1RMC4RNOS1NOS2NOS3OPRK1OXTRRAMP1RAMP2RAMP3SCN5ASSTR1SSTR2SSTR3SSTR4SSTR5dacAdacBdacCfolPftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Acetic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 known ✓ | P03372 | 1/20 | 0.43 |
| ▸ | SMPD1 | P17405 | 4/20 | 0.48 |
| ▸ | FDPS | P14324 | 2/20 | 0.48 |
| ▸ | CES2 | O00748 | 1/20 | 0.44 |
| ▸ | PPARG | P37231 | 5/20 | 0.43 |
| ▸ | PPARD | Q03181 | 5/20 | 0.43 |
| ▸ | PPARA | Q07869 | 5/20 | 0.43 |
| ▸ | HDAC11 | Q96DB2 | 4/20 | 0.43 |
| ▸ | TSHR | P16473 | 3/20 | 0.43 |
| ▸ | GPR84 | Q9NQS5 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | TLR2 | O60603 | 2/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.43 |
| ▸ | FABP4 | P15090 | 2/20 | 0.43 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.43 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.43 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | PDE4A | P27815 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acetic Acid SCHEMBL4367052 | 1.00 | SMPD1 (0.48) | SMPD1FDPSCES2PPARGPPARD | |
| Acetic Acid SCHEMBL11691620 | 1.00 | SMPD1 (0.48) | SMPD1FDPSCES2PPARGPPARD | |
| Acetic Acid SCHEMBL9224621 | 1.00 | SMPD1 (0.48) | SMPD1FDPSCES2PPARGPPARD | |
| Acetic Acid SCHEMBL3140123 | 0.98 | FDPS (0.47) | SMPD1FDPSCES2PPARGPPARD | |
| Bicarbonate SCHEMBL27083092 | 0.93 | SMPD1 (0.50) | SMPD1FDPSCES2PPARGPPARD | |
| Bicarbonate SCHEMBL1689393 | 0.91 | FDPS (0.48) | SMPD1FDPSCES2PPARGPPARD | |
| Pivalate SCHEMBL3414635 | 0.89 | SMPD1 (0.47) | SMPD1FDPSCES2PPARGPPARD | |
| Methacrylic Acid SCHEMBL9938003 | 0.88 | SMPD1 (0.43) | SMPD1FDPSCES2PPARGPPARD | |
| Glycolic Acid SCHEMBL23466939 | 0.88 | SMPD1 (0.46) | SMPD1FDPSPPARGPPARDPPARA | |
| Propionic Acid SCHEMBL4938562 | 0.88 | SMPD1 (0.46) | SMPD1FDPSPPARGPPARDPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3665308-A1 | METHODS AND MATERIALS FOR ASSESSING AND TREATING CANCER | The Johns Hopkins University (US) | 2020-06-17 | — | — | EP | disclosed |
| WO-2019067092-A1 | METHODS AND MATERIALS FOR ASSESSING AND TREATING CANCER | THE JOHNS HOPKINS UNIVERSITY (US) | 2019-04-04 | — | — | WO | disclosed |
| US-7642344-B2 | Methods and compositions for determining the sequence of nucleic acid molecules | OPERON BIOTECHNOLOGIES, INC. (US) | 2010-01-05 | — | — | US | disclosed |
| US-20080009613-A1 | Methods and compositions for determining the sequence of nucleic acid molecules | OPERON BIOTECHNOLOGIES, INC. (US) | 2008-01-10 | — | — | US | disclosed |
| US-7247434-B2 | Methods and compositions for determining the sequence of nucleic acid molecules | OPERON BIOTECHNOLOGIES, INC. (US) | 2007-07-24 | — | — | US | disclosed |
| US-7052846-B2 | Methods and compositions for analyzing nucleic acid molecules utilizing sizing techniques | OPERON BIOTECHNOLOGIES, INC. (US) | 2006-05-30 | — | — | US | disclosed |
| US-20060057566-A1 | METHODS AND COMPOSITIONS FOR ANALYZING NUCLEIC ACID MOLECULES UTILIZING SIZING TECHNIQUES | QIAGEN GENOMICS, INC. (US) | 2006-03-16 | — | — | US | disclosed |
| US-20040115694-A1 | Methods and compositions for determining the sequence of nucleic acid molecules | QIAGEN GENOMICS, INC. | 2004-06-17 | — | — | US | disclosed |
| US-6623928-B2 | Determining the sequence of a nucleic acid; obtain sample, incubate with labeled probe, separate labeled nucleotide sequences, remove label, detect labels | QIAGEN GENOMICS, INC. | 2003-09-23 | — | — | US | disclosed |
| US-6613508-B1 | Spectrometry; electrophoresis; chromatography; separation; cleavage; labels; probes; primers; hybridization; use of tags in a wide variety of nucleic acid reactions where separation of nucleic acid molecules based on size is required | QIAGEN GENOMICS, INC. | 2003-09-02 | — | — | US | disclosed |
| EP-0990047-B1 | METHODS AND COMPOSITIONS FOR ANALYZING NUCLEIC ACIDS BY MASS SPECTROMETRY | QIAGEN GENOMICS INC (US) | 2003-05-14 | — | — | EP | disclosed |
| US-20020119456-A1 | Methods and compositions for determining the sequence of nucleic acid molecules | AGILENT TECHNOLOGIES, INC. | 2002-08-29 | — | — | US | disclosed |
| US-6361940-B1 | IMMOBILIZATION; GENETIC ENGINEERING | QIAGEN GENOMICS, INC. | 2002-03-26 | — | — | US | disclosed |
| US-6312893-B1 | GENERATING TAGGED NUCLEIC ACID FRAGMENTS WHICH ARE COMPLEMENTARY TO SELECTED TARGET NUCLEIC ACID MOLECULE; SEPARATION OF TAGGED FRAGMENTS; CLEAVING THE TAGS; DETECTING TAGS BY NON-FLUORESCENT SPECTROMETRY OR POTENTIOMETRY | QIAGEN GENOMICS, INC. | 2001-11-06 | — | — | US | disclosed |
| EP-0990047-A2 | METHODS AND COMPOSITIONS FOR ANALYZING NUCLEIC ACID MOLECULES UTILIZING SIZING TECHNIQUES | Rapigene, Inc. (US) | 2000-04-05 | — | — | EP | disclosed |
| EP-0958378-A2 | COMPOSITIONS AND METHODS FOR ENHANCING HYBRIDIZATION SPECIFICITY | Rapigene, Inc. (US) | 1999-11-24 | — | — | EP | disclosed |
| EP-0952228-A2 | Compositions and methods for enhancing hybridization specificity | Rapigene, Inc. (US) | 1999-10-27 | — | — | EP | disclosed |
| WO-1999005319-A9 | METHODS AND COMPOUNDS FOR ANALYZING NUCLEIC ACIDS BY MASS SPECTROMETRY | RAPIGENE INC (US) | 1999-06-17 | — | — | WO | disclosed |
| WO-1999005319-A2 | METHODS AND COMPOUNDS FOR ANALYZING NUCLEIC ACIDS BY MASS SPECTROMETRY | RAPIGENE, INC. (US) | 1999-02-04 | — | — | WO | disclosed |
| WO-1998013527-A2 | COMPOSITIONS AND METHODS FOR ENHANCING HYBRIDIZATION SPECIFICITY | RAPIGENE, INC. (US) | 1998-04-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080009613-A1 | Methods and compositions for determining the sequence of nucleic acid molecules | CPSF6, RNMT, POLM | ESR1 1236/4885SMPD1 3704/4885FDPS 2010/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.